By Fineline Cube 
Novo Nordisk (NYSE: NVO) announced that Zhou Xiaping, Senior Vice President and President of Greater China, will depart the company effective March 31 2026. Yan Cai, currently Head of Market, Medical & Registration (MM&R) in Novo Nordisk’s International Operations, has been appointed as the new Senior Vice President and President of Greater China.
Leadership Transition Details
| Item | Detail |
|---|---|
| Outgoing Executive | Zhou Xiaping |
| Position | Senior Vice President and President, Greater China |
| Last Working Day | March 31 2026 |
| Incoming Executive | Yan Cai |
| Current Role | Head of Market, Medical & Registration (MM&R), International Operations |
| Effective Date | Appointment effective immediately |
| Reporting Structure | Reports to Emil Kongshøj Larsen, EVP International Operations |
Financial Results Timing
Novo Nordisk will release its fourth‑quarter 2025 financial results before the opening of the Nasdaq Copenhagen Stock Exchange on February 4 2026. The results will provide insight into GLP‑1 market performance and Greater China business trajectory under new leadership.
Strategic Implications
- Continuity Assurance: Yan Cai’s MM&R experience ensures seamless transition amid Novo Nordisk’s ongoing expansion in China’s diabetes and obesity markets
- Market Significance: Greater China represents a $3 billion+ annual revenue market for Novo Nordisk, driven by Wegovy and Ozempic demand
- Leadership Stability: Appointment reflects Novo Nordisk’s commitment to maintaining regional expertise while accelerating digital and regulatory capabilities
Forward‑Looking Statements
This brief contains forward‑looking statements regarding leadership transition timelines and financial performance expectations. Actual results may differ due to market conditions, regulatory changes, and competitive dynamics in the Greater China region.-Fineline Info & Tech